ArticleBMJ open2025
Assessing the carbon footprint of French academic clinical trials using the NIHR method.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Remifentanil for Rapid Sequence Induction and Intubation in Full Stomach Patient Compared to Muscle Relaxant. A Non-inferiority Simple Blind Randomized Controlled Trial
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) With Poor Prognosis: TOCILAM"
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis project aimed to assess the applicability of the National Institute for Health and Care Research (NIHR) tool to French academic studies and identify the carbon hotspots, with a view to discussing ways of mitigating their environmental impact.
designRetrospective analysis.
settingA completed single-centre phase I haematology trial TOCILAM (NCT04547062) and a completed multicentre phase III in intensive care REMICRUSH (NCT03960801).
participantsTOCILAM had a total number of 12 participants and REMICRUSH had a total number of 1150 participants.
main outcome measuresTotal carbon emissions from each trial and the hotspots of those emissions.
resultsThe carbon footprint of the TOCILAM and REMICRUSH studies was estimated at 3.2 and 5.8 tonnes of CO DISCUSSION: The NIHR tool is easily applicable to the context of French academic clinical studies. The total estimated carbon footprint of the two clinical trials was generally lower than what has been reported in the literature for academic studies. However, areas for improvement have been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.